血清β2-微球蛋白和C-反应蛋白水平检测在多发性骨髓瘤患者诊断、疗效监测和预后判断中的临床意义

摘要

Objective To study the clinical significance of determination of plasma levels ofβ2-MG and CRP in patients with multiple myeloma (MM).Methods Plasma levels of TNF-α and β2-m were determined in 42 patients with multiple myeloma before and after chemotherapy, and it also been determined in 50 healthy controls.Results The plasma levels of β2-MG and CRP in patients with multiple myeloma were significantly higher than those controls (P ＜ 0.01 ).The plasma levels of β2-MG and CRP were decreases after the chemotherapy.And there had a long surval time in patients with a lower plasma levels of β2-MG and CRP than those with a higher level.Conclusion The determination of plasma levels ofβ2-MG and ClP might be helpful for diagnosis , curative effect monitoring and prognosis in patients with multiple myeloma.%目的 测定β2-微球蛋白和C-反应蛋白在多发性骨髓瘤(MM)患者血清中含量的变化,探讨β2-微球蛋白和C-反应蛋白水平对多发性骨髓瘤患者临床诊断、疗效检测和预后判断的意义.方法 分别测定我院收治的42例MM患者血清β2-微球蛋白和C-反应蛋白治疗前后的水平,以50例体检健康者为对照组.结果 多发性骨髓瘤患者其血清β2-微球蛋白和C-反应蛋白水平明显高于对照组;化疗显效后血清β2-微球蛋白和C-反应蛋白水平比化疗前明显下降;低水平β2-微球蛋白和C-反应蛋白患者的存活时间相对较长.结论 血清β2-微球蛋白和C-反应蛋白水平检测可作为多发性骨髓瘤患者诊断、疗效监测和预后判断的重要指标.